Latest News - Oklahoma Society of Clinical Oncology

Pfizer Oncology announces a new FDA-approved indication for XALKORI® (crizotinib). 

Read the Full Prescribing Information

Read More

AstraZeneca announces additional approval for ENHERTU® (fam-trastuzumab deruxtecan-nxki)

AstraZeneca recently announced that ENHERTU® (fam-trastuzumab deruxtecan-nxki) is now approved for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti–HER2-based regimen either: in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy.1 ENHERTU has Boxed […]

Read More

FDA approves a new indication for LYNPARZA® (olaparib)

The US Food and Drug Administration (FDA) has approved a new indication for LYNPARZA® (olaparib) for the adjuvant treatment of adult patients with deleterious or suspected deleterious gBRCAm, human epidermal growth factor receptor 2 (HER2)-negative, high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Select patients for therapy based on an FDA-approved […]

Read More

Register Now for OSCO’s “Best of” San Antonio Breast Cancer Symposium® Virtual Symposium to be held March 19, 2022

The Oklahoma Society of Clinical Oncology, Inc. would like to invite you to attend our 2022 Spring meeting. Join your colleagues to hear highlights from this state-of-the art symposium on the experimental biology, etiology, prevention, diagnosis and therapy of breast cancer and premalignant breast disease. The “Best of” SABCS is an officially licensed program of the San Antonio […]

Read More

Natera Achieves Milestone of Enrolling First 1,000 Patients in its BESPOKE CRC Study

Clinical utility study in stage I-IV colorectal cancer (CRC) evaluates how adjuvant treatment decisions are impacted by using the Signatera™ MRD test Natera, Inc. (NASDAQ: NTRA) a global leader in cell-free DNA testing, today announced a milestone with over 100 sites initiated and 1,000 patients enrolled across the U.S. in its BESPOKE CRC study, a prospective, […]

Read More

Additional FDA approval for KEYTRUDA® announced

Merck announces that the FDA has approved KEYTRUDA® (pembrolizumab) Injection 100 mg for the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB or IIC melanoma following complete resection.  •  PD-L1 diagnostic testing is not required prior to initiating treatment with KEYTRUDA in these patients.  Before prescribing KEYTRUDA® (pembrolizumab), please read the Prescribing Information. The Medication […]

Read More

KEYTRUDA® (pembrolizumab) indicated for adjuvant treatment of Renal Cell Carcinoma

KEYTRUDA® (pembrolizumab) is indicated for the adjuvant treatment of patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. SELECTED SAFETY INFORMATION Severe and Fatal Immune-Mediated Adverse Reactions •  KEYTRUDA is a monoclonal antibody that belongs to a class of drugs that bind to […]

Read More

Merck announces new FDA approval for KEYTRUDA®

Merck would like to inform you that the FDA has approved KEYTRUDA® (pembrolizumab) Injection 100 mg, in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test.    •  PD-L1 diagnostic testing is required prior to initiating treatment with […]

Read More

Novartis announces new treatment approval for SCEMBLIX®

Novartis is pleased to announce that SCEMBLIX® (asciminib) tablets is now approved for the treatment of adult patients with: ·  Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with 2 or more tyrosine kinase inhibitors (TKIs) ○     This indication is approved under accelerated approval based on major molecular response (MMR). Continued approval […]

Read More

Oncopeptides withdraws Pepaxto® in US, scale down organization and focus on R&D

October 22, 2021     Subject: Voluntary withdrawal of PEPAXTO® (melphalan flufenamide) for the treatment of relapsed or refractory multiple myeloma   Dear Healthcare Provider:  This letter is to inform you about important information regarding PEPAXTO in the United States.  On October 22, 2021, Oncopeptides announced the decision to voluntarily withdraw the US accelerated approval for […]

Read More